Chronic sildenafil in men with diabetes and erectile dysfunction

Antonio Aversa, Roberto Bruzziches, Cristiana Vitale, Giuseppe Marazzi, Davide Francomano, Giuseppe Barbaro, Giovanni Spera, Giuseppe M C Rosano

Research output: Contribution to journalArticlepeer-review


Erectile dysfunction frequently represents a neurovascular complication of diabetes mellitus, and it has been calculated that almost 50% of diabetic men will have erectile dysfunction within 6 years after diagnosis. Penile endothelial and smooth muscle cell dysfunction are due to molecular pathway abnormalities (i.e., activation of PKC, increased oxidative stress and over-production of advanced-glycosylation end products). The response rate to oral drug therapies, such as sildenafil, is lower than in most other groups. Because therapeutic alternatives (i.e., intracavernous injections with vasoactive agents) are not curative, clinical trials aimed to demonstrate rehabilitative effects with daily phosphodiesterase type-5 inhibitors are ongoing. If this approach proves successful, it will determine many advantages over the intracavernosal treatment and potentially induce sexual rehabilitation.

Original languageEnglish
Pages (from-to)451-464
Number of pages14
JournalExpert Opinion on Drug Metabolism and Toxicology
Issue number3
Publication statusPublished - Jun 2007


  • Diabetes
  • Endothelial dysfunction
  • Erectile dysfunction
  • Phosphodiesterase type-5
  • Rehabilitation

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Chronic sildenafil in men with diabetes and erectile dysfunction'. Together they form a unique fingerprint.

Cite this